We read with interest the article by Yin et al1 on efficacy and safety of drug-coated balloon (DCB) angioplasty using paclitaxel for dysfunctional arteriovenous fistula (AVF). To date, several randomized controlled trials have been conducted to determine the efficacy of DCB in AVF stenosis.1-7 However, diversity in study populations and end point selections led to controversy surrounding the benefit of DCB over high-pressure balloon (HPB) angioplasty (Table 1). The study by Yin et al used imaging instead of a clinical outcome as the primary end point.